Overview
The U.S. Preventive Services Task Force recommends lung cancer screening (LCS) with low-dose computed tomography for adults aged 50 to 80 years who have smoked 20+ pack years and currently smoke or have quit within the past 15 years. LCS may be a teachable moment and an opportunity to deliver tobacco cessation treatment; however, how best to integrate high-quality tobacco cessation treatment into the LCS context is uncertain. The Smoking Cessation at Lung Examination (SCALE) Collaboration was created to accelerate understanding of the implementation and effectiveness of smoking cessation interventions in the context of LCS by supporting cross-project research across 8 funded randomized controlled clinical trials. This 2-part webinar series will discuss the findings and lessons learned from this initiative.
- Describe several investigational SCALE Collaboration smoking cessation interventions in the context of lung cancer screening.
- Develop and increase insight into the implementation and effectiveness of the delivery of tobacco cessation treatments in varied lung cancer screening clinical contexts.
- Examine best practices and implications associated with the delivery of tobacco cessation treatments in the context of lung cancer screening.
- Describe several investigational SCALE Collaboration smoking cessation interventions in the context of lung cancer screening.
- Develop and increase insight into the implementation and effectiveness of the delivery of tobacco cessation treatments in varied lung cancer screening clinical contexts.
- Examine best practices and implications associated with the delivery of tobacco cessation treatments in the context of lung cancer screening.